

FIRM NEWS

Schulte Advises Deep Track Capital on \$158 Million Biotech Financing Deal

April 18, 2024

Schulte Roth & Zabel represented lead financier Deep Track Capital in an investment in TORL BioTherapeutics, a clinical-stage biotechnology company involved in the discovery and development of immunotherapies designed to improve and extend the lives of patients with cancer worldwide.

The oversubscribed \$158 million Series B-2 financing spearheaded by Deep Track Capital, an investment firm focused exclusively on the life sciences industry, will advance a clinical-stage Antibody-Drug Conjugate.

The Schulte team was led by partner Michael Flynn and special counsel John Doherty.

Related People



**Michael
Flynn**
Partner
New York



**John
Doherty**
Special Counsel
New York

Practices

MERGERS AND ACQUISITIONS